Why Your Healthcare Facility Needs Nozin® Nasal Sanitizer® 

Increased Protection Against Risk of Infections

The nose is a reservoir for bacteria that escape typical hygiene protocols such as hand washing.  Nozin® Nasal Sanitizer® antiseptic equips health professionals and patients with a safe and effective nasal shield that helps provide protection from infection causing pathogens. In addition, Nozin NOVA programs provide a suite of services to guide facilities in the successful implementation of Nozin® Nasal Sanitizer® for your facility.

Review Clinical Outcomes

Importantly, Nozin® Nasal Sanitizer® antiseptic use in hospitals is well documented with clinical outcomes.  Be sure to review information on this research by clicking here.

The Critical Nature of Nasal Carriage

Nozin® Nasal Sanitizer®

  • Nose is reservoir for prolific bacterial colonization(5)
  • Warm, moist, CO2 rich nasal vestibule hospitable for bacteria
  • 30% of population carry Staph aureus in the nose(1)
  • 80% of wound infections can be traced to patient nasal bacteria DNA(2)
  • 40% reduction in ICU infections when decolonization protocols include the nose(3)
  • Anterior nasal vestibule primary colonization site(6)
  • Nose is significant source of HAI in patients
  • Hand and nose contact occurs every 4 mins on average
  • Frequent nose touching compromises hand hygiene
  • Studies: Reducing nasal carriage reduces HAI(7,8)
  • Nasal carriage is not addressed by typical procedures:
    • Hard Surface Disinfecting
    • Equipment Decontamination
    • Hand Hygiene

The HAI toll is devastating

  • 2 million cases/yr
  • 100,000 patient deaths/yr
  • 4th largest killer
  • More than AIDS, Breast Cancer, Auto Accidents COMBINED

The cost of HAI to hospitals is high

  • Cost hospitals up to $45 billion per year
  • Cost increasingly borne by facilities due to lack of reimbursement for HAI
  • Infection costs degrade financial performance
  • Staph aureus infection cost ~$30k per case, over $14.5 billion per year

Benefits of Nasal Sanitizer® use in your healthcare facility

 An important, new paradigm, Nozin® Nasal Sanitizer® offers an innovative tool for fast and easy nasal carriage reduction that is clinically proven.(9) This infection control breakthrough can be used to:

  • Decreased bacterial burden contributes to reduced risk of infection
  • Improve prevention
  • Provide sense of more secure, healthier environment 
  • Increase attention to wellness of patient satisfaction

Nasal Sanitizer® can provide a new tool to help in the
control of nasal colonization by potentially pathogenic bacteria.

  • Nasal Sanitizer® targets a critical point of carriage
  • Kills 99.99% of germs
  • Broad spectrum efficacy
  • Proven safe and effective
  • Clinically shown to reduce nasal carriage, without antibiotics(9)


1. Olsen K et al. Prevalence and population structure of Staphylococcus aureus nasal carriage in healthcare workers in a general population. The Tromsø Staph and Skin Study. Epidemiol Infect 141:143–152, 2013.
2. Coates, T et al. Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses and future prospects. J Antimicrob Chemother 64,9-15, 2009.
3. Nicas M, Jones RM. Relative contributions of four exposure pathways to influenza infection risk, Risk Analysis. 29:1292-1303, 2009.
4. Huang SS et al. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med 368(24):2255-65, 2013.
5. Lemon KP et al. Comparative analysis of the bacterial microbiota of the human nostril and oropharynx. Mbio 1(3):1-9, 2012.
6. Cole AM et al. Determinants of Staphylococcus aureus nasal carriage. Clin Diagn Lab Immunol 8(6):1064-1069, 2001.
7. Bode LGM et al. Preventing surgical-site infections in nasal carriers of staphylococcus aureus. N Engl J Med 362(1):9-17, 2010.
8. Camus C et al. Randomized comparison of 2 protocols to prevent acquisition of methicillin-resistant Staphylococcus aureus: results of a 2-center study involving 500 patients. Infect Control Hosp Epidemiol 32(11):1064-72, 2011. 9. Steed L, et al. Reduction of nasal Staphylococcus aureus carriage. American Journal of Infection Control 42(8): 841-846, 2014.

Learn more about Nasal Sanitizer®

We encourage you to explore the entire site. Read the Frequently Asked Questions page. Also, learn about protocols and solutions for your facility. Please feel free to submit the form below or contact us with any questions you may have.

© 2004-2024 Global Life Technologies Corp. All rights reserved. Nozin® Nasal Sanitizer® antiseptic is an OTC topical antiseptic drug and no claim is made that it has an effect on any specific disease.